Australian Cancer Technology Announces Change in Board Of Directors.

SYDNEY, Australia -- Australian Cancer Technology (AustCancer) (ASX:ACU) today announced that Art Benvenuto has resigned as a member of the board of directors in lieu of an active role serving as a strategic consultant to the board and as an advisor to senior management.

"We are extremely pleased to have Art's continued involvement with AustCancer," said Dr. Richard Opara, chairman of the board. "As a prominent leader in the life sciences community, Art's broad experience and sound counsel will continue to benefit the company as we prepare to establish a presence in the U.S. biotechnology marketplace."

Mr. Benvenuto said, "AustCancer has an important portfolio of technologies and potential products and I look forward to working closely with the company as an advisor."

About Australian Cancer Technology (www.austcancer.com.au)

Australian Cancer Technology (AustCancer) is an international biotechnology company developing a broad oncology-related product portfolio. The company has acquired the North American marketing rights for RP101, a promising pancreatic cancer drug currently in Phase II clinical studies. AustCancer's Pentrys(TM) anti-cancer vaccine is being evaluated in prostate cancer patients in Phase IIb clinical studies and the company is advancing immune enhancing adjuvants in three Phase I and II cancer trials. The company also markets revisys(TM), a branded line of medical nutritionals designed for people with special needs, including those undergoing cancer treatments. AustCancer is traded on the Australian Stock Exchange (ASX) under the symbol ACU. The company has established a Level 1 ADR stock program in the U.S. trading under the symbol AUCJY and also is listed on the Xetra exchange, the electronic trading system of the Frankfurt Stock Exchange, trading under the symbol CBS.